Abstract A017: A retrospective clinical study on the 5-year and 10-year survival rates of postoperative malignant tumor patients treated with DC-CIK

Abstract Objective: This study aimed to evaluate the impact of combined dendritic cell (DC) and cytokine-induced killer (CIK) cell therapy on the long-term survival rates of postoperative patients with malignant tumors. Methods: We conducted a retrospective study analyzing follow-up data from 66 out of 151 postoperative malignant tumor patients who received DC-CIK combination therapy between 2005 and 2015. These patients had various solid tumors, including lung cancer (21 cases), gastric cancer (15 cases), and colorectal cancer (12 cases), among others. Patients were stratified by tumor stage: Stage I (10 cases), Stage II (23 cases), Stage III (30 cases), and Stage IV (3 cases). The treatment protocol was stage-based: Stage I patients received 1-2 courses; Stage II received 2-3 courses (the first course combined with low-dose chemotherapy); Stage III received 3-4 courses (the first two courses combined with low-dose chemotherapy); Stage IV received 4 or more courses (the first three courses preceded by low-dose chemotherapy). The initial interval between courses was 1-3 months, which could later be extended to 3-5 months. Results: The median follow-up time exceeded 10 years. Among all 66 evaluable patients, 14 (21.2%) died from tumor recurrence. The overall 5-year survival rate was 83.3% (55/66), and the 10-year survival rate was 78.8% (52/66). Stratified analysis showed that survival rates were significantly correlated with tumor stage. No tumor-related deaths occurred in Stage I patients (n=10). The 10-year survival rate for Stage II patients (n=23) was 87% (20/23). For Stage III patients (n=30), the 10-year survival rate was 73% (22/30). All three Stage IV patients died during the follow-up period. Conclusion: Retrospective analysis indicates that postoperative adjuvant DC-CIK cell immunotherapy is positively correlated with favorable long-term survival rates in malignant tumor patients, with high 10-year survival rates observed particularly in early-stage (I-III) patients. The combination of DC and CIK cells may produce synergistic anti-tumor effects by targeting tumor cells with different antigen presentation mechanisms. These findings provide long-term follow-up evidence supporting the potential of DC-CIK therapy as an adjuvant treatment for postoperative tumors, warranting further validation through prospective randomized controlled trials. Citation Format: Weihong daiqing gao, Sun, Changyou Danni zhu, Li, Xiaofang Wei, Shishun Xie. A retrospective clinical study on the 5-year and 10-year survival rates of postoperative malignant tumor patients treated with DC-CIK [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr A017.